Leerink Swann assumed coverage on shares of Health Catalyst (NASDAQ:HCAT) in a research note published on Monday, The Fly reports. The firm issued an outperform rating and a $55.00 price target on the stock.
A number of other analysts have also recently commented on the company. SunTrust Banks assumed coverage on Health Catalyst in a research report on Monday. They set a buy rating and a $53.00 price objective for the company. Evercore ISI assumed coverage on Health Catalyst in a research report on Monday. They set an outperform rating and a $50.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average price target of $51.29.
Health Catalyst stock opened at $42.94 on Monday. Health Catalyst has a one year low of $36.29 and a one year high of $49.85.
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.
See Also: Moving Average (MA)
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.